FindMyKOL
Clinical trialNCT02534129TerminatedPhase 1/2Interventional

Topical Use of Difinsa53™ to Prevent Radiation Dermatitis

NCT02534129 is a phase 1/2 interventional trial sponsored by ProTechSure Scientific, Inc.. As of 21 Nov 2026, it was terminated. It studies Aquaphor and Difinsa53 in Radiodermatitis. The registry lists an enrollment of 13 participants at 1 site in 1 country. The registry lists a start date of 31 Aug 2015 and a primary completion date of 31 Mar 2016.

SponsorProTechSure Scientific, Inc.Enrollment13Radiodermatitis
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT02534129
FieldValue
Registry IDNCT02534129
StatusTerminated
PhasePhase 1/2
Study typeInterventional trial
Lead sponsorProTechSure Scientific, Inc.
Enrollment13
Registered sites1
Countries1
ConditionsRadiodermatitis
DrugsAquaphor and Difinsa53
Start31 Aug 2015
Primary completion31 Mar 2016
Study completion31 Mar 2016
Last update posted6 Oct 2017

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Phase II trial of the silibin containing cream, Difinsa53 to determine efficacy in delaying, ameliorating, or preventing radiation dermatitis in patients with breast cancer undergoing whole breast radiation.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Colorado, United States1 site
  • Poudre Valley Health System

    Fort Collins

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColorado: 1 siteCO1KansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AquaphorDifinsa53
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT02534129

Each answer restates registry values shown on this page.

What is NCT02534129?

NCT02534129 is a phase 1/2 interventional trial sponsored by ProTechSure Scientific, Inc.. It studies Aquaphor and Difinsa53 in Radiodermatitis.

Who leads NCT02534129?

The registry names Joshua Petit, MD (principal investigator, UC Health, Poudre Valley Hospital) as the overall official.

Where does NCT02534129 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT02534129 study?

The registered drug and biological interventions are Aquaphor and Difinsa53.

When did NCT02534129 end?

The registry lists a primary completion date of 31 Mar 2016 and a study completion date of 31 Mar 2016. The sponsor last updated the record on 6 Oct 2017.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.